UY37370A - Métodos para tratar esofagitis eosinofílica - Google Patents
Métodos para tratar esofagitis eosinofílicaInfo
- Publication number
- UY37370A UY37370A UY0001037370A UY37370A UY37370A UY 37370 A UY37370 A UY 37370A UY 0001037370 A UY0001037370 A UY 0001037370A UY 37370 A UY37370 A UY 37370A UY 37370 A UY37370 A UY 37370A
- Authority
- UY
- Uruguay
- Prior art keywords
- methods
- administering
- esophagitis
- eosinophyl
- treat
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 206010030216 Oesophagitis Diseases 0.000 title 1
- 208000006881 esophagitis Diseases 0.000 title 1
- 206010064212 Eosinophilic oesophagitis Diseases 0.000 abstract 3
- 201000000708 eosinophilic esophagitis Diseases 0.000 abstract 3
- 229940124624 oral corticosteroid Drugs 0.000 abstract 3
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 230000002327 eosinophilic effect Effects 0.000 abstract 1
- 210000003238 esophagus Anatomy 0.000 abstract 1
- 230000006698 induction Effects 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 238000012423 maintenance Methods 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 210000002438 upper gastrointestinal tract Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662376703P | 2016-08-18 | 2016-08-18 | |
| US201762461317P | 2017-02-21 | 2017-02-21 | |
| US201762489292P | 2017-04-24 | 2017-04-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY37370A true UY37370A (es) | 2018-01-02 |
Family
ID=61197039
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001037370A UY37370A (es) | 2016-08-18 | 2017-08-18 | Métodos para tratar esofagitis eosinofílica |
Country Status (11)
| Country | Link |
|---|---|
| US (6) | US10105315B2 (zh) |
| EP (1) | EP3500264A4 (zh) |
| JP (2) | JP6929934B2 (zh) |
| KR (3) | KR20230167146A (zh) |
| AU (2) | AU2017312660B2 (zh) |
| CA (1) | CA3034264A1 (zh) |
| NZ (1) | NZ750754A (zh) |
| RU (1) | RU2766577C2 (zh) |
| TW (2) | TWI777515B (zh) |
| UY (1) | UY37370A (zh) |
| WO (1) | WO2018035393A1 (zh) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3403654T3 (da) * | 2009-10-01 | 2019-08-26 | Adare Dev I L P | Oralt administrerede kortikosteroidsammensætninger |
| TWI633891B (zh) | 2013-06-04 | 2018-09-01 | 再生元醫藥公司 | 藉由投與ｉｌ－４ｒ抑制劑以治療過敏及增強過敏原－特異之免疫療法的方法 |
| TWI682781B (zh) | 2013-07-11 | 2020-01-21 | 美商再生元醫藥公司 | 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法 |
| WO2015034678A2 (en) | 2013-09-06 | 2015-03-12 | Aptalis Pharmatech, Inc. | Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis |
| CN106062000B (zh) | 2014-02-28 | 2021-05-28 | 瑞泽恩制药公司 | 通过施用il-4r拮抗剂治疗皮肤感染的方法 |
| TWI777515B (zh) * | 2016-08-18 | 2022-09-11 | 美商愛戴爾製藥股份有限公司 | 治療嗜伊紅性食道炎之方法 |
| MA46098A (fr) | 2016-09-01 | 2019-07-10 | Regeneron Pharma | Méthodes de prévention ou de traitement de l'allergie par administration d'un antagoniste d'il-4 r |
| EP3793597A1 (en) | 2018-05-13 | 2021-03-24 | Regeneron Pharmaceuticals, Inc. | Methods for treating atopic dermatitis by administering an il-4r inhibitor |
| US11672959B2 (en) * | 2019-01-18 | 2023-06-13 | Intersect Ent, Inc. | Expandable member systems and methods for drug delivery |
| AU2020240132A1 (en) | 2019-03-21 | 2021-09-16 | Regeneron Pharmaceuticals, Inc. | Combination of IL-4/IL-13 pathway inhibitors and plasma cell ablation for treating allergy |
| CA3147068A1 (en) | 2019-08-05 | 2021-02-11 | Regeneron Pharmaceuticals, Inc. | Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r antagonist |
| US11106813B2 (en) * | 2019-09-20 | 2021-08-31 | International Business Machines Corporation | Credentials for consent based file access |
| US11328089B2 (en) | 2019-09-20 | 2022-05-10 | International Business Machines Corporation | Built-in legal framework file management |
| US11321488B2 (en) | 2019-09-20 | 2022-05-03 | International Business Machines Corporation | Policy driven data movement |
| US11188680B2 (en) | 2019-09-20 | 2021-11-30 | International Business Machines Corporation | Creating research study corpus |
| US11327665B2 (en) | 2019-09-20 | 2022-05-10 | International Business Machines Corporation | Managing data on volumes |
| US11443056B2 (en) | 2019-09-20 | 2022-09-13 | International Business Machines Corporation | File access restrictions enforcement |
| EP4054589A4 (en) * | 2019-10-01 | 2023-10-25 | Ellodi Pharmaceuticals, L.P. | METHODS OF TREATING EOSINOPHILIC EOSOPHAGITIS AND REDUCING CANDIDIASIS |
| US11075010B1 (en) * | 2020-03-19 | 2021-07-27 | Insight RX, Inc. | Pharmacology model optimization based on distributed data acquisition |
| US20210330900A1 (en) * | 2020-04-22 | 2021-10-28 | Topical Sinus Therapeutics, Inc. | TARGETED ADMINISTRATION TO THE OROPHARYNX OF VISCOUS OR DRY POWDER FLUTICASONE PROPIONATE AND RELATED CORTICOSTEROIDS FOR THE TREATMENT OF EOSINOPHILIC ESOPHAGITIS (EoE) |
| EP4153300A1 (en) * | 2020-05-22 | 2023-03-29 | Regeneron Pharmaceuticals, Inc. | Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor |
| AU2022260478A1 (en) * | 2021-04-20 | 2023-10-26 | Ellodi Pharmaceuticals, L.P. | Methods of treating esophageal strictures |
| TW202308653A (zh) * | 2021-04-26 | 2023-03-01 | 美商普雷西斯精密藥品股份有限公司 | 以神經活性類固醇進行治療的方法 |
Family Cites Families (100)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1170188A (en) | 1967-09-15 | 1969-11-12 | Bayer Ag | N-trityl-imidazoles and salts and uses thereof |
| SE378109B (zh) | 1972-05-19 | 1975-08-18 | Bofors Ab | |
| US4080448A (en) | 1974-11-13 | 1978-03-21 | Mirsky Louis H | Method of treating cellular stress |
| US4335121A (en) | 1980-02-15 | 1982-06-15 | Glaxo Group Limited | Androstane carbothioates |
| SE8004580L (sv) | 1980-06-19 | 1981-12-20 | Draco Ab | Farmaceutisk beredning |
| CY1359A (en) | 1981-02-02 | 1987-08-07 | Schering Corp | Aromatic heterocyclic esters of steroids, their preparation and pharmaceutical compositions containing them |
| GB8630913D0 (en) | 1986-12-24 | 1987-02-04 | Glaxo Group Ltd | Pharmaceutical compositions |
| US5446070A (en) | 1991-02-27 | 1995-08-29 | Nover Pharmaceuticals, Inc. | Compositions and methods for topical administration of pharmaceutically active agents |
| ZA892859B (en) | 1988-04-22 | 1989-12-27 | Advanced Polymer Systems Inc | Porous particles in preparations involving immiscible phases |
| GB9002375D0 (en) | 1990-02-02 | 1990-04-04 | Pfizer Ltd | Triazole antifungal agents |
| US5278175A (en) | 1990-02-02 | 1994-01-11 | Pfizer Inc. | Triazole antifungal agents |
| GR1001529B (el) | 1990-09-07 | 1994-03-31 | Elmuquimica Farm Sl | Μέ?οδος για την λήψη νέων 21-εστέρων της 16-17-ακετάλης της πρ να-1,4-διενο-3,20-διόνης. |
| CA2101773A1 (en) | 1991-01-31 | 1992-08-01 | Toyoichi Tanaka | Interpenetrating-polymer network phase-transition gels |
| EP0735884B1 (en) | 1993-12-20 | 2000-04-26 | Minnesota Mining And Manufacturing Company | Flunisolide aerosol formulations |
| GB9517062D0 (en) | 1995-08-18 | 1995-10-25 | Scherer Ltd R P | Pharmaceutical compositions |
| US5863910A (en) * | 1996-01-12 | 1999-01-26 | Bolonick; Joel | Treatment of chronic inflammatory disorders of the gastrointestinal tract |
| DE19606151C2 (de) | 1996-02-20 | 1999-05-12 | Losan Pharma Gmbh | Ibuprofen-Brausezubereitung sowie Verfahren zur Herstellung derselben |
| DE69739967D1 (de) | 1996-06-14 | 2010-09-30 | Kyowa Hakko Kirin Co Ltd | Eine im Mund schnell zerfallende Tablette |
| US8071128B2 (en) | 1996-06-14 | 2011-12-06 | Kyowa Hakko Kirin Co., Ltd. | Intrabuccally rapidly disintegrating tablet and a production method of the tablets |
| SE9604486D0 (sv) | 1996-12-05 | 1996-12-05 | Astra Ab | Novel formulation |
| GB9707934D0 (en) | 1997-04-18 | 1997-06-04 | Danbiosyst Uk | Improved delivery of drugs to mucosal surfaces |
| RO118174B1 (ro) | 1997-08-21 | 2003-03-28 | Aventis Pharma Deutschland Gmbh | Lac de unghii şi utilizarea acestuia |
| EP1058538B9 (en) | 1998-03-06 | 2013-01-02 | Aptalis Pharma S.r.l. | Fast disintegrating tablets |
| FR2781156B1 (fr) | 1998-07-20 | 2001-06-29 | Lafon Labor | Composition pharmaceutique destinee notamment a la prevention et au traitement des radiomucites et des chimiomucites |
| US6596298B2 (en) | 1998-09-25 | 2003-07-22 | Warner-Lambert Company | Fast dissolving orally comsumable films |
| MXPA01010676A (es) | 1999-04-23 | 2003-08-20 | Leo Pharm Prod Ltd | Composicion farmaceutica de vitamina d o un analogo de vitamina d y al menos un corticoesteroide. |
| DE60031504T2 (de) | 1999-09-11 | 2007-04-05 | Glaxo Group Ltd., Greenford | Fluticasonpropionat arzneizubereitung |
| KR100446101B1 (ko) | 2000-12-07 | 2004-08-30 | 주식회사 삼양사 | 수난용성 약물의 서방성 제형 조성물 |
| US20030050312A1 (en) | 2001-03-12 | 2003-03-13 | Hjorth Thyge Borup | Novel tablets and capsules and a process for its preparation |
| WO2002072150A2 (en) | 2001-03-13 | 2002-09-19 | Angiotech Pharmaceuticals Inc. | Micellar drug delivery vehicles and uses thereof |
| WO2002092057A1 (fr) | 2001-05-10 | 2002-11-21 | Yamanouchi Pharmaceutical Co., Ltd. | Comprimes a desintegration rapide dans la cavite orale et procede de production desdits comprimes |
| US6872405B2 (en) | 2001-05-10 | 2005-03-29 | Yamanouchi Pharmaceutical Co., Ltd. | Quick-disintegrating tablet in buccal cavity and manufacturing method thereof |
| US6656493B2 (en) | 2001-07-30 | 2003-12-02 | Wm. Wrigley Jr. Company | Edible film formulations containing maltodextrin |
| FR2831820B1 (fr) | 2001-11-05 | 2004-08-20 | Ethypharm Sa | Comprime orodispersible presentant une grande homogeneite et son procede de preparation |
| US20030206978A1 (en) | 2001-11-29 | 2003-11-06 | Bob Sherwood | Agglomerated particles including an active agent coprocessed with silicified microcrystalline cellulose |
| US20040009212A1 (en) | 2002-01-30 | 2004-01-15 | Pharma Power Biotec Co. Ltd. | Mucoadhesive thermoresponsive medicament-carrier composition |
| JP4173670B2 (ja) | 2002-03-08 | 2008-10-29 | 旭化成ファーマ株式会社 | 口腔内崩壊製剤 |
| WO2003093344A1 (en) | 2002-05-03 | 2003-11-13 | Janssen Pharmaceutica N.V. | Polymeric microemulsions |
| WO2004021997A2 (en) | 2002-09-06 | 2004-03-18 | Microbia, Inc. | Inhibitors of fungal invasion |
| WO2004023984A2 (en) | 2002-09-13 | 2004-03-25 | Smith C Steven | Novel composition and method for treatment of upper respiratory conditions |
| US7731947B2 (en) | 2003-11-17 | 2010-06-08 | Intarcia Therapeutics, Inc. | Composition and dosage form comprising an interferon particle formulation and suspending vehicle |
| ATE454132T1 (de) | 2003-01-21 | 2010-01-15 | Nippon Shinyaku Co Ltd | Rasch in der mundhöhle schmelzende tablette |
| SI1587514T1 (sl) | 2003-01-31 | 2006-10-31 | Orexo Ab | Hitro ucinkujoc farmacevtski sestavek |
| US20040208833A1 (en) | 2003-02-04 | 2004-10-21 | Elan Pharma International Ltd. | Novel fluticasone formulations |
| US8012505B2 (en) | 2003-02-28 | 2011-09-06 | Alk-Abello A/S | Dosage form having a saccharide matrix |
| US20040265375A1 (en) | 2003-04-16 | 2004-12-30 | Platteeuw Johannes J. | Orally disintegrating tablets |
| US20050009848A1 (en) | 2003-07-10 | 2005-01-13 | Icn Pharmaceuticals Switzerland Ltd. | Use of antivirals against inflammatory bowel diseases |
| US20060134054A1 (en) | 2003-12-19 | 2006-06-22 | Council Of Scientific And Industrial Research | Polymer composition for pH dependent dissolution behavior and process for preparation thereof |
| PL1748756T3 (pl) | 2004-03-10 | 2009-10-30 | Bayer Schering Pharma Ag | Kompozycje zawierające molekularnie zdyspergowany drospirenon |
| US8545881B2 (en) | 2004-04-19 | 2013-10-01 | Eurand Pharmaceuticals, Ltd. | Orally disintegrating tablets and methods of manufacture |
| PL1634586T3 (pl) | 2004-09-09 | 2007-07-31 | Laboratorio Medinfar Produtos Farm S A | Szybko rozpadające się w wodzie tabletki domperidonu |
| US20070020330A1 (en) | 2004-11-24 | 2007-01-25 | Medpointe Healthcare Inc. | Compositions comprising azelastine and methods of use thereof |
| US20060292099A1 (en) | 2005-05-25 | 2006-12-28 | Michael Milburn | Treatment of eye disorders with sirtuin modulators |
| TW200800142A (en) | 2005-09-09 | 2008-01-01 | Univ Manitoba | Fast-disintegrating epinephrine tablets for buccal or sublingual administration |
| US8324192B2 (en) | 2005-11-12 | 2012-12-04 | The Regents Of The University Of California | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
| US8497258B2 (en) * | 2005-11-12 | 2013-07-30 | The Regents Of The University Of California | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
| US8679545B2 (en) | 2005-11-12 | 2014-03-25 | The Regents Of The University Of California | Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract |
| JP2007158225A (ja) | 2005-12-08 | 2007-06-21 | Canon Inc | 露光装置 |
| CN1985799B (zh) | 2005-12-19 | 2011-11-09 | 量子高科（北京）研究院有限公司 | 口腔崩解制剂的制备方法 |
| BRPI0620578A2 (pt) | 2005-12-27 | 2011-12-06 | Jubilant Organosys Ltd | composição farmacêutica que dissolve na boca e processo para o preparo da mesma |
| US20080260655A1 (en) | 2006-11-14 | 2008-10-23 | Dov Tamarkin | Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses |
| EP1958613A1 (en) | 2007-02-15 | 2008-08-20 | Polichem S.A. | Dermal film-forming liquid formulations for drug release to skin |
| US20090074862A1 (en) | 2007-04-13 | 2009-03-19 | Luigi Schioppi | Low-dose doxepin formulations and methods of making and using the same |
| US20150231156A1 (en) * | 2007-11-13 | 2015-08-20 | Meritage Pharma, Inc. | Corticosteroid compositions |
| US20090131386A1 (en) | 2007-11-13 | 2009-05-21 | Meritage Pharma, Inc. | Compositions for the treatment of inflammation of the gastrointestinal tract |
| US20090123551A1 (en) | 2007-11-13 | 2009-05-14 | Meritage Pharma, Inc. | Gastrointestinal delivery systems |
| US20100216754A1 (en) * | 2007-11-13 | 2010-08-26 | Meritage Pharma, Inc. | Compositions for the treatment of inflammation of the gastrointestinal tract |
| PL3354276T3 (pl) | 2007-11-13 | 2020-09-21 | Meritage Pharma, Inc. | Kompozycje do leczenia zapalenia przewodu pokarmowego |
| BRPI0820997A2 (pt) | 2007-12-10 | 2014-12-23 | Eurand Inc | Comprimidos de desintegração oral compreendendo difenidramina. |
| BRPI0821761A2 (pt) | 2007-12-21 | 2015-06-16 | Eurand Inc | Composições de comprimidos de desintegração oral de temazepam |
| JP2009173552A (ja) | 2008-01-21 | 2009-08-06 | Lion Corp | 胃腸薬 |
| RS51649B (en) | 2008-07-21 | 2011-10-31 | Dr. Falk Pharma Gmbh. | PHARMACEUTICAL FORMULATION FOR THE TREATMENT OF THE UPPER DIGESTIVE TRACT |
| CN102112114A (zh) | 2008-08-08 | 2011-06-29 | 麦克内尔-Ppc股份有限公司 | 使用三氯蔗糖作为制粒剂 |
| DK2328553T3 (da) | 2008-08-20 | 2020-08-24 | Univ California | Corticosteroider til behandling af inflammatoriske sygdomme i mave-tarm-kanalen |
| BRPI0924069A2 (pt) | 2009-01-15 | 2017-03-28 | Nestec Sa | métodos de diagnosticar e tratar disfagia |
| JP2012518655A (ja) | 2009-02-23 | 2012-08-16 | アプタリス ファーマテック インコーポレイテッド | プロトンポンプ阻害剤を含む制御放出組成物 |
| US20110097401A1 (en) | 2009-06-12 | 2011-04-28 | Meritage Pharma, Inc. | Methods for treating gastrointestinal disorders |
| CN102596237A (zh) | 2009-09-07 | 2012-07-18 | Dbv技术公司 | 治疗嗜酸细胞性食管炎的方法 |
| DK3403654T3 (da) | 2009-10-01 | 2019-08-26 | Adare Dev I L P | Oralt administrerede kortikosteroidsammensætninger |
| EP2506835B1 (en) | 2009-11-30 | 2019-06-12 | Adare Pharmaceuticals, Inc. | Compressible-coated pharmaceutical compositions and tablets and methods of manufacture |
| US20120164080A1 (en) * | 2010-06-24 | 2012-06-28 | Meritage Pharma, Inc. | Methods of treatment for esophageal inflammation |
| CA2819663C (en) | 2010-12-02 | 2019-12-24 | Aptalis Pharmatech, Inc. | Rapidly dispersing granules, orally disintegrating tablets and methods |
| EP2665408B1 (en) | 2011-01-18 | 2021-08-11 | University Health Network (UHN) | Device for swallowing impairment detection |
| EP2667777B1 (en) | 2011-01-28 | 2016-08-10 | Nestec S.A. | Apparatuses for diagnosing swallowing dysfunction |
| BR112014014558A8 (pt) | 2011-12-16 | 2017-07-04 | Atopix Therapeutics Ltd | composição farmacêutica, uso de um antagonista de crth2 e de um inibidor de bomba de prótons, e, kit para o tratamento de esofagite eosinofílica |
| WO2014016754A2 (en) | 2012-07-26 | 2014-01-30 | Lupin Limited | Pharmaceutical compositions of proton pump inhibitor |
| TWI682781B (zh) | 2013-07-11 | 2020-01-21 | 美商再生元醫藥公司 | 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法 |
| WO2015034678A2 (en) | 2013-09-06 | 2015-03-12 | Aptalis Pharmatech, Inc. | Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis |
| EP2886108B2 (de) | 2013-12-23 | 2022-11-02 | Dr. Falk Pharma Gmbh | Optimierte pharmazeutische Formulierung zur Behandlung von entzündlichen Veränderungen des Ösophagus |
| US10294517B2 (en) | 2014-03-17 | 2019-05-21 | Children's Hospital Medical Center | Genetic test for determining susceptibility for eosinophilic esophagitis |
| US10176301B2 (en) | 2014-09-11 | 2019-01-08 | Meritage Pharma, Inc. | Systems, methods, and software for providing a patient-reported outcome measure of dysphagia patients with eosinophilic esophagitis |
| US9980975B2 (en) * | 2015-01-22 | 2018-05-29 | Ems S.A. | Dosage forms containing fluticasone propionate for the treatment of inflammatory conditions of the esophagus |
| US10869592B2 (en) | 2015-02-23 | 2020-12-22 | Uroviu Corp. | Handheld surgical endoscope |
| EP3448391A4 (en) | 2016-04-27 | 2019-12-18 | AbbVie Inc. | METHODS OF TREATING DISEASES IN WHICH IL-13 ACTIVITY IS HARMFUL WITH ANTI-IL-13 ANTIBODIES |
| US10076494B2 (en) | 2016-06-16 | 2018-09-18 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
| TWI777515B (zh) | 2016-08-18 | 2022-09-11 | 美商愛戴爾製藥股份有限公司 | 治療嗜伊紅性食道炎之方法 |
| CA3090832A1 (en) | 2018-02-21 | 2019-08-29 | Adare Pharmaceuticals Us, L.P. | Methods of managing eosinophilic esophagitis |
| EP4054589A4 (en) | 2019-10-01 | 2023-10-25 | Ellodi Pharmaceuticals, L.P. | METHODS OF TREATING EOSINOPHILIC EOSOPHAGITIS AND REDUCING CANDIDIASIS |
| WO2022020464A1 (en) | 2020-07-21 | 2022-01-27 | Ellodi Pharmaceuticals, L.P. | Modified release rapidly disintegrating compositions of proton pump inhibitors |
| AU2022260478A1 (en) | 2021-04-20 | 2023-10-26 | Ellodi Pharmaceuticals, L.P. | Methods of treating esophageal strictures |
-
2017
- 2017-08-17 TW TW110114767A patent/TWI777515B/zh active
- 2017-08-17 TW TW106127874A patent/TWI728172B/zh active
- 2017-08-18 KR KR1020237040942A patent/KR20230167146A/ko not_active Application Discontinuation
- 2017-08-18 KR KR1020217023832A patent/KR20210095973A/ko active Application Filing
- 2017-08-18 AU AU2017312660A patent/AU2017312660B2/en active Active
- 2017-08-18 RU RU2019105805A patent/RU2766577C2/ru active
- 2017-08-18 CA CA3034264A patent/CA3034264A1/en active Pending
- 2017-08-18 JP JP2019508847A patent/JP6929934B2/ja active Active
- 2017-08-18 NZ NZ750754A patent/NZ750754A/en unknown
- 2017-08-18 US US15/680,301 patent/US10105315B2/en active Active
- 2017-08-18 EP EP17842162.4A patent/EP3500264A4/en active Pending
- 2017-08-18 KR KR1020197007310A patent/KR20190039769A/ko active Application Filing
- 2017-08-18 WO PCT/US2017/047474 patent/WO2018035393A1/en unknown
- 2017-08-18 UY UY0001037370A patent/UY37370A/es not_active Application Discontinuation
-
2018
- 2018-09-14 US US16/131,812 patent/US11026887B2/en active Active
-
2020
- 2020-08-13 US US16/992,671 patent/US20200368147A1/en not_active Abandoned
-
2021
- 2021-05-03 US US17/306,458 patent/US11684571B2/en active Active
- 2021-07-15 US US17/376,996 patent/US11896710B2/en active Active
- 2021-08-11 JP JP2021131290A patent/JP2021178866A/ja active Pending
-
2023
- 2023-09-11 US US18/244,500 patent/US20230414498A1/en active Pending
- 2023-09-20 AU AU2023233115A patent/AU2023233115A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US11896710B2 (en) | 2024-02-13 |
| TW201808304A (zh) | 2018-03-16 |
| US20180133145A1 (en) | 2018-05-17 |
| US20190008760A1 (en) | 2019-01-10 |
| US10105315B2 (en) | 2018-10-23 |
| KR20190039769A (ko) | 2019-04-15 |
| NZ750754A (en) | 2023-02-24 |
| JP2019528272A (ja) | 2019-10-10 |
| RU2766577C2 (ru) | 2022-03-15 |
| US20200368147A1 (en) | 2020-11-26 |
| RU2019105805A (ru) | 2020-09-18 |
| JP2021178866A (ja) | 2021-11-18 |
| JP6929934B2 (ja) | 2021-09-01 |
| KR20210095973A (ko) | 2021-08-03 |
| US11026887B2 (en) | 2021-06-08 |
| RU2019105805A3 (zh) | 2020-11-13 |
| EP3500264A1 (en) | 2019-06-26 |
| AU2023233115A1 (en) | 2023-10-12 |
| KR20230167146A (ko) | 2023-12-07 |
| US20210275438A1 (en) | 2021-09-09 |
| AU2017312660A1 (en) | 2019-03-07 |
| EP3500264A4 (en) | 2020-04-29 |
| TWI728172B (zh) | 2021-05-21 |
| US20210346278A1 (en) | 2021-11-11 |
| TW202206079A (zh) | 2022-02-16 |
| WO2018035393A1 (en) | 2018-02-22 |
| AU2017312660B2 (en) | 2023-06-29 |
| US20230414498A1 (en) | 2023-12-28 |
| US11684571B2 (en) | 2023-06-27 |
| TWI777515B (zh) | 2022-09-11 |
| CA3034264A1 (en) | 2018-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY37370A (es) | Métodos para tratar esofagitis eosinofílica | |
| CL2017002242A1 (es) | Método para tratar un tumor cerebral | |
| MX2019006864A (es) | Tratamiento de una enfermedad del tracto gastrointestinal con un inhibidor de factor de necrosis tumoral (tnf). | |
| PE20190338A1 (es) | Metodos de tratamiento de trastornos del desarrollo con gaboxadol | |
| CR20140086A (es) | Tratamientos de combinación para hepatitis c | |
| MX2019006821A (es) | Tratamiento de una enfermedad del tracto gastrointestinal con un inhibidor de cinasa de janus (jak) y dispositivos. | |
| ECSP15008695A (es) | Combinaciones farmacéuticas que comprenden un inhibidor de b-raf, un inhibidor de egfr y opcionalmente un inhibidor de pi3k-alfa | |
| CR20180253A (es) | Composiciones terapéuticas para el tratamiento del virus de unmunodeficiencia humana | |
| CL2017000050A1 (es) | Terapia de combinación para el cáncer | |
| NI201400112A (es) | Tratamiento del cáncer con inhibidores tor cinasa | |
| RU2017116740A (ru) | Комбинации для лечения рассеянного склероза | |
| UY33164A (es) | Metodo de tratamiento | |
| PH12017500747B1 (en) | Heterocyclic compound | |
| BR112016029437A2 (pt) | métodos para tratamento e prevenção de doenças de instabilidade vascular | |
| AR102308A1 (es) | Composición farmacéutica para usar en el tratamiento o prevención de deficiencias de vitaminas y minerales en pacientes sometidos a cirugía de bypass gástrico | |
| DOP2023000155A (es) | Tratamiento y terapia de mantenimiento para el cáncer de vejiga con gemcitabina | |
| MX2018015208A (es) | Andrografolido para tratar formas progresivas de esclerosis multiple. | |
| AR095594A1 (es) | Métodos para tratar infecciones en pacientes con sobrepeso y obesos usando antibióticos | |
| EA201790220A1 (ru) | Лечение симптомов, связанных с андроген-депривационной терапией | |
| AR109380A1 (es) | Métodos para tratar esofagitis eosinofílica | |
| AR099416A1 (es) | Terapia combinada para la hipertensión resistente | |
| CR20140480A (es) | Metodos para tratar el cancer usando inhibidor de pi3k e inhibidor de mek | |
| AR102494A1 (es) | Métodos para tratar enfermedades oculares | |
| RU2012135942A (ru) | Способ лечения больных желчекаменной болезнью первой стадии | |
| AR106645A1 (es) | Composiciones terapéuticas para el tratamiento del virus de inmunodeficiencia humana |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20230626 |